How close are we to aging reversal drugs?
In our longevity market deck, you will find everything you need to understand the market
SUMMARY
How close are we to aging reversal drugs? We are close to the first human proof-of-concept, but not close to routine aging reversal treatment.
The field has crossed an important line: partial reprogramming is no longer only a mouse-paper or investor-deck story. ER-100 has reached a regulated human Phase 1 trial, which makes 2026 the first real clinical test of this aging-reversal idea.
The strongest near-term evidence is not whole-body rejuvenation. It is local, tissue-specific rejuvenation, especially in the eye, where delivery, structure, and visual function can be measured more cleanly than in most organs.
The eye matters because it turns an abstract aging claim into a testable medical question. If retinal ganglion cells show molecular rejuvenation and patients see better, the field gets its first serious human signal.
But even a positive ER-100 result would not mean we can reverse aging generally. It would mean one damaged tissue may be partly rescued under controlled conditions, which is a major milestone but still a narrow one.
The biggest gap is between moving biomarkers and improving human function. Epigenetic clocks, methylation patterns, and biological-age readouts are useful, but they cannot replace vision, strength, immune resilience, cognition, frailty, or disease outcomes.
Pill-based approaches are more mature clinically, but they look less like true reversal. Rapamycin, metformin, senolytics, autophagy enhancers, omega-3, vitamin D, and multivitamins mostly point to pathway modulation, modest biomarker shifts, or disease-risk delay.
The scale of supplement effects is useful because it disciplines the conversation. Month-scale epigenetic-clock changes over two or three years are interesting, but they are not what the public imagines when it hears “aging reversal.”
Senolytics show the field’s translation problem clearly. The mechanism is credible, animal evidence is strong, and some human disease signals exist, but larger trials can still fail when the biology meets real patients.
Regulation is another quiet bottleneck. Companies cannot simply ask for approval of an “aging reversal” drug today, so early products will enter through glaucoma, NAION, Alzheimer’s, diabetic eye disease, immune aging, liver disease, or other specific indications.
The most credible near-term path is not one universal therapy. It is a sequence of narrow wins: eye first, then possibly liver, immune system, fibrosis, neurodegeneration, or other tissues where delivery and endpoints are practical.
So the honest answer is neither hype nor dismissal. We are now testing aging reversal biology in humans, but the field still needs functional improvement, durability, safety, and replication before it becomes real medicine.
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
Can we make old cells act young again?
Yes, we can already make old cells behave younger in specific lab and animal settings.
That’s not a problem. The real question is whether we can do it safely, repeatedly, and usefully in humans.
The core mechanism getting attention today is partial epigenetic reprogramming. Instead of turning an adult cell all the way back into a stem cell, researchers briefly expose it to reprogramming factors so it keeps its identity but loses some age-associated molecular marks. That is why the field suddenly feels more serious: it is no longer just about slowing damage, but about asking whether cellular age can be pushed backward.
The strongest early proof came from the eye. In a 2020 Nature paper from David Sinclair’s Harvard-linked group, OSK reprogramming restored youthful DNA-methylation patterns and improved optic-nerve regeneration and visual function in mice. The eye matters because it is unusually testable: researchers can inject locally, track structure, measure visual function, and avoid exposing the whole body.
Since then, the signal has moved one level up. Life Biosciences later reported nonhuman-primate NAION data where ER-100 reduced visual-function deficits and showed methylation-pattern restoration in retinal ganglion cells. That is a much more relevant model than a mouse, although the important caveat is that these primate results are still mostly company-reported rather than fully peer-reviewed human evidence.
Has anyone injected an aging reversal drug into a human?
Yes, but only in a first safety trial. That is a milestone, not yet a victory lap.
The major fresh signal is ER-100 from Life Biosciences, the company co-founded by David Sinclair. In January 2026, the FDA cleared the company’s IND for a Phase 1 trial in optic neuropathies. In June 2026, Life Biosciences announced that the first patient had been dosed. Wired also reported that the study is expected to involve roughly 18 adults and is primarily testing safety and side effects.
That changes the status of the field. Until recently, partial reprogramming lived in papers, animal models, and investor decks. Now there is a regulated human test, with a defined product, a defined tissue, a defined dose, and long-term follow-up.
But we should be strict about what has been proven. The ClinicalTrials.gov record describes the trial as first-in-human, Phase 1, and focused on safety and tolerability after a single dose in people with open-angle glaucoma or NAION. Participants are followed with eye exams, lab testing, body-fluid sampling, quality-of-life questionnaires, and long-term monitoring for up to five years.
If you want more recent data on this point, please see our latest longevity market report.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Can we reverse age-related vision loss right now?
No, we can test whether it is possible, but we cannot yet say we can do it in humans.
The eye is the most advanced test case because the biology, delivery route, and endpoints line up unusually well. ER-100 is delivered locally into the eye, targets retinal ganglion cells, and is being tested in diseases where optic-nerve damage causes measurable visual loss. That is a much cleaner first battlefield than trying to rejuvenate the whole body.
There are three signals that make the eye credible. First, the 2020 Nature mouse work showed improved visual function in models of optic-nerve injury, glaucoma-like damage, and natural aging. Second, Life Biosciences reported nonhuman-primate NAION results showing reduced visual-function deficits and preserved axon-density measures. Third, the current human trial includes long-term vision outcomes even though its primary purpose is safety.
The interpretation is important. If ER-100 shows a vision signal in humans, it would be the first serious evidence that partial reprogramming can improve an age-related human disease. That would be huge. But it would still be “local ocular rejuvenation,” not a general aging reversal drug.
For now, we are at the “can we rescue one damaged tissue?” stage. That is already a big deal, but it is still far from “can we make the whole organism younger?”
Can we make the whole body younger with one treatment?
No, systemic aging reversal is still the hardest version of the problem.
Whole-body rejuvenation sounds like the natural next step, but biologically it is a different problem. A retinal ganglion cell, a liver cell, a muscle stem cell, an immune cell, and a neuron do not age in the same way. They also do not tolerate the same delivery systems or the same safety risks.
A 2024 Nature Communications review made this distinction clearly: tissue-specific partial reprogramming is more likely to reach therapy first because full organism-level rejuvenation faces major delivery and organ-specificity constraints. That matches what we see in the market. Life Biosciences is starting with the eye. Its ER-300 liver program is still preclinical. NewLimit is working toward epigenetic therapies but, based on 2025–2026 reporting, still sits before first-in-human trials. Retro Biosciences has entered humans with an autophagy-focused brain-aging program, not a whole-body reprogramming treatment.
The funding signal is stronger than the clinical signal. Altos Labs, Retro Biosciences, NewLimit, and Life Biosciences all point to serious capital moving into cellular rejuvenation. But money is not the same as validation. It tells us sophisticated investors now believe the category is worth testing, not that the core risk has disappeared.
Everything considered together, the first products will probably be tissue-by-tissue therapies. Eye first, maybe liver or immune aging later, then more complex organs. A single systemic “make me younger” drug is still much further away.
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, illustrates yearly VC funding for longevity startups
Can a pill reverse aging instead of gene therapy?
Not today. The pill-like approaches look more like aging-slowing or pathway-tuning than true reversal.
The most mature pill-like candidates are mTOR inhibitors, metformin, senolytics, and autophagy enhancers. These are important, but they work differently from epigenetic reprogramming. They may improve stress resistance, immune function, inflammation, proteostasis, or metabolic health. They do not currently reset old cells into younger versions of themselves in a broad, proven human way.
Rapamycin is probably the most serious example. A Lancet Healthy Longevity review screened more than 18,000 articles and included 19 human studies. The review found improvements in some aging-related physiological parameters, especially in immune, cardiovascular, and skin-related systems. That is meaningful because rapamycin has one of the strongest animal-longevity records. Still, the human evidence is a patchwork of pathway signals and small studies, rather than a clear demonstration of broad rejuvenation.
Metformin is even more misunderstood. The TAME trial is designed to test whether metformin can delay multiple age-related diseases, not whether it reverses aging. As of today, the credible public position is that TAME remains a regulatory and trial-design milestone, not a source of proven anti-aging efficacy. Anyone claiming the trial has already shown large lifespan or multi-disease benefits is getting ahead of the evidence.
Retro Biosciences is a useful fresh signal here. Its first human program, RTR242, targets autophagy in Alzheimer’s disease. That shows where the pill field is going: very specific aging-linked mechanisms, tested first through diseases where regulators can measure outcomes.
So it looks like pills may become geroscience drugs before they become aging reversal drugs. Useful, maybe even very useful, but not the same category as reprogramming.
Can supplements already slow biological aging?
Yes, slightly, but the effect sizes are months, not decades.
The best recent supplement signals are surprisingly measurable, but they should be interpreted with discipline. In the DO-HEALTH trial, published in Nature Aging in 2025, omega-3 supplementation slowed several DNA-methylation aging clocks by roughly 2.9 to 3.8 months over three years. The effect was stronger when omega-3 was combined with vitamin D and exercise on some measures.
Then in March 2026, a Nature Medicine analysis from the COSMOS randomized clinical trial found that a daily multivitamin slowed several epigenetic aging clocks in older adults. Harvard’s summary put the effect at about four months less biological aging over two years.
Those numbers are useful because they give us scale. A four-month clock shift over two or three years is not nothing, especially in randomized trials. But it is also nowhere near what people imagine when they hear “aging reversal.” It looks more like nutritional optimization showing up in biomarkers, especially among older adults who may have deficiencies.
Finally, the supplement evidence also shows why clocks can mislead the public. A biological-age number can move, but the reader still has to ask whether people get stronger, avoid disease, stay independent longer, or live longer. Today, the answer is still incomplete.
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Can we measure if someone really got younger?
Partly. We can measure aging signals, but we cannot yet certify true rejuvenation from a clock alone.
Epigenetic clocks are useful because they compress DNA-methylation patterns into a biological-age estimate. That lets researchers test interventions much faster than waiting for mortality, frailty, dementia, cancer, or cardiovascular outcomes.
But the clocks are not a final judge. A 2024 Nature Reviews Genetics review described epigenetic clocks as powerful machine-learning tools, while also emphasizing major computational and interpretation problems. Different clocks capture different things. Some are closer to chronological age, some to mortality risk, some to inflammation or disease burden. That means a therapy can look good on one clock and unimpressive on another.
This is why the strongest future evidence will combine three layers: a molecular signal, a tissue signal, and a functional signal. In the eye, that means methylation changes plus retinal or optic-nerve structure plus vision. In muscle, it means molecular rejuvenation plus muscle composition plus strength or gait speed. In the immune system, it means immune-cell changes plus better vaccine response, fewer infections, or improved resilience.
Can we remove old bad cells from the body?
Yes, in principle, but senolytics have not yet proven broad human rejuvenation.
Senolytics target senescent cells, which are damaged cells that stop dividing but keep releasing inflammatory signals. The idea is appealing because senescent cells accumulate with age and contribute to tissue dysfunction. Removing them works well in many animal models.
The human story is more uneven. Dasatinib plus quercetin has been tested in small human studies, including idiopathic pulmonary fibrosis and diabetic kidney disease settings. Those studies showed feasibility and biological signals, but they were not enough to prove broad rejuvenation.
UNITY Biotechnology gives a more concrete market signal. Its senolytic eye drug UBX1325 showed encouraging Phase 2 data in diabetic macular edema, including reports of durable vision improvement through 48 weeks in one study. But in March 2025, the larger Phase 2b ASPIRE trial failed to meet its primary endpoint, and the company’s stock dropped sharply. That is exactly the kind of mixed outcome we should expect in a young field: plausible mechanism, some clinical signal, but fragile translation.
So senolytics are not dead. They look more like disease-specific drugs than universal anti-aging drugs.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Can we regenerate an aging immune system?
A little, but this is still small-study territory.
The immune system is one of the most practical places to look because immune aging shows up in infections, vaccine response, cancer surveillance, inflammation, and recovery. If we could restore immune function in older adults, that would count as a real healthspan win even without making every organ younger.
The TRIIM trial is the classic provocative signal. In 2019, a small study of nine men used a combination of growth hormone, DHEA, and metformin, originally aimed at thymus regeneration. It reported epigenetic-age reversal and immune-related improvements. The result was striking, but the study was small, not the kind of large randomized evidence that changes medical practice.
The follow-on TRIIM-X trial is designed as an expanded pilot study, which tells us the signal was interesting enough to continue but still not settled. In parallel, rapamycin and rapalog studies keep pointing toward immune-aging modulation. A recent ClinicalTrials.gov listing for RESTOR is explicitly trying to identify dose and timing of rapamycin or everolimus in older adults, including immunological, physical-performance, and cognitive effects.
As of now, immune rejuvenation is one of the more credible near-term aging-drug angles because endpoints can be practical. But it still needs larger trials showing that older people actually resist disease better, not only that their biomarkers look younger.
If you want more recent data on this point, please see our latest longevity market report.
Can regulators approve an “aging reversal” drug?
Not as a broad aging drug today. Companies have to enter through diseases.
This is one of the biggest hidden bottlenecks. Regulators approve therapies for specific indications, populations, and endpoints. Aging itself is not treated like a standard disease indication by the FDA, EMA, or Health Canada. A 2025 scoping review of gerotherapeutic regulation made the point directly: current systems are still structured around disease-specific therapies rather than systemic aging interventions.
That is why the field looks the way it does. ER-100 is not being tested as “anti-aging.” It is being tested in glaucoma and NAION. Retro’s RTR242 is not being tested as “brain rejuvenation.” It is being aimed at Alzheimer’s disease. UBX1325 was tested in diabetic macular edema. TAME uses metformin to test delay of multiple age-related diseases, but still has to translate aging biology into concrete clinical events.
This means the first approved “aging reversal” products probably will not be labeled that way. They will look like eye drugs, liver drugs, immune drugs, fibrosis drugs, or neurodegeneration drugs whose mechanism happens to target aging biology.
For the reader, the key is that regulatory status will lag scientific ambition. A therapy could become an aging-biology breakthrough while still entering the market as a narrow disease treatment.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
What would convince us an aging reversal drug is real?
A real aging reversal drug needs functional improvement, durability, and safety in humans.
The bar should be higher than a press release, a mouse paper, or a biological-age number. For ER-100, the meaningful signal would be treated patients showing visual improvement or slowed deterioration, with retinal or optic-nerve evidence, acceptable inflammation or tumor safety, and follow-up beyond the first few months.
For systemic drugs, the bar is even higher. A serious candidate would need to improve multiple aging-linked outcomes at once: fewer infections, better physical function, delayed disease onset, improved cognition, or reduced frailty. A methylation clock moving by a few months can support the case, but it cannot carry the whole argument.
Durability matters because a one-time molecular reset may fade. Safety matters because reprogramming biology sits close to cell identity, growth control, and cancer risk. Dose control matters because too little reprogramming does nothing, while too much could push cells toward dangerous states.
So the strongest future evidence will look boring in the best way: randomized trials, predefined endpoints, longer follow-up, tissue-specific safety data, and replication by groups that are not financially tied to the product.
If you want more recent data on this point, please see our latest longevity market report.
So how close are we to aging reversal drugs?
We are close to the first human proof-of-concept, not close to routine aging reversal treatment.
The field has clearly moved. In 2020, the strongest evidence was a mouse-eye Nature paper. By 2024–2025, companies had primate data, disease-specific programs, and larger funding rounds. In 2026, ER-100 became the first FDA-cleared partial-reprogramming therapy dosed in humans, while supplement and geroscience trials kept adding modest biomarker evidence.
But the distance between “first human dosed” and “approved aging reversal drug” is still large. Phase 1 has to show safety. Then small efficacy studies need to show a real functional signal. Then larger controlled trials have to confirm the benefit, define the right patients, and monitor long-term risk.
So, to conclude, we are now testing aging reversal in humans, but we are not yet treating aging reversal in humans. Local, disease-specific therapies could produce the first credible human signals in the next few years. Broad systemic rejuvenation remains a much harder, later category.
| Check we made | Status today | What it means |
|---|---|---|
| Make old cells show younger molecular patterns | Done preclinically | Partial reprogramming can reverse some age-associated markers in cells and animal tissues. |
| Restore function in an aged animal tissue | Done in specific models | Mouse-eye studies and company-reported primate eye data suggest functional rescue is possible in the optic system. |
| Dose a partial-reprogramming therapy in humans | Just started | ER-100 reached a Phase 1 human trial in 2026, which is the category’s biggest recent milestone. |
| Prove human aging reversal works clinically | Not done | No published human efficacy result yet shows ER-100 or any reprogramming therapy reversing aging in patients. |
| Reverse one local age-related disease | Soon testable | The eye is the first serious proving ground because delivery and endpoints are unusually clean. |
| Reverse aging across the whole body | Not close | Delivery, tissue specificity, durability, and cancer safety remain unresolved. |
| Use pills to slow aging biology | Partly done | Rapamycin, metformin, autophagy, and senolytic approaches are active, but they look more like pathway modulation than true reversal. |
| Move biological-age clocks in humans | Done modestly | Omega-3 and multivitamin trials show month-scale clock changes, not large rejuvenation. |
| Prove clock changes mean better health | Not done enough | Clocks are useful research tools, but function and clinical outcomes still matter more. |
| Get regulators to approve “aging reversal” directly | Not today | Companies must test specific diseases first, so early products will probably look like eye, liver, immune, or neurodegeneration drugs. |
| Reach consumer availability | Not close | The field is in early clinical testing, not prescription-ready or wellness-clinic-ready reversal. |
This chart, featured in our longevity market deck, illustrates how revenue is distributed across customer segments in the longevity market
OUR METHODOLOGY
To answer a question as broad as “are aging reversal drugs close?”, we did not rely on a single headline, trial, company, or scientific claim. We broke the question into the dimensions that actually decide the answer: whether old cells can be made younger in principle, whether that has restored function in animals, whether any therapy has reached humans, whether the effect is local or systemic, whether biomarkers translate into real health outcomes, and whether regulators have a practical path to approval.
For each dimension, we looked at the freshest credible signals and weighted them by how directly they moved the field forward. A first-in-human trial carries more weight than a preclinical result. A functional improvement carries more weight than a biomarker shift alone. A regulated clinical endpoint carries more weight than funding activity or company ambition.
That structure is what makes the answer more solid. The field has clearly moved from theory toward early human testing, especially in the eye. But the evidence still points to local, disease-specific proof-of-concept before anything like broad, routine aging reversal.
We treated company-reported primate data as important but not final. It matters because nonhuman-primate evidence is more relevant than mouse evidence, but it still carries less weight than peer-reviewed human efficacy data.
We treated epigenetic clocks as useful supporting evidence, not as proof by themselves. A clock change becomes more convincing when it lines up with tissue-level evidence and real functional improvement.
We also separated aging-slowing approaches from aging-reversal approaches. Rapamycin, metformin, senolytics, autophagy enhancers, omega-3, vitamin D, and multivitamins may matter for geroscience, but they do not currently prove broad human rejuvenation.
Key sources used for this analysis include: Nature on OSK reprogramming and restored vision in mice, Harvard Medical School’s summary of the mouse-eye work, Life Biosciences on FDA IND clearance for ER-100, ClinicalTrials.gov on the ER-100 Phase 1 trial, Life Biosciences on the first ER-100 patient dosed, Wired on first-human ER-100 dosing, Life Biosciences on nonhuman-primate NAION data, Life Biosciences on ER-300 liver and ER-100 methylation data, Nature Communications on reprogramming-induced rejuvenation, and Nature Aging on epigenetic rejuvenation strategies.
Additional sources used include: The Lancet Healthy Longevity on rapamycin in humans, AFAR on the TAME trial, the peer-reviewed TAME trial design paper, Nature Aging on the DO-HEALTH omega-3, vitamin D, and exercise clock study, Nature Medicine on the COSMOS multivitamin epigenetic-clock analysis, Harvard Gazette on the COSMOS multivitamin result, Nature Reviews Genetics on epigenetic clocks, UNITY Biotechnology’s UBX1325 ASPIRE Phase 2b topline result, ClinicalTrials.gov on TRIIM-X, and ClinicalTrials.gov on the RESTOR rapamycin and everolimus trial.
This chart, featured in our longevity market deck, shows how longevity plan technology has evolved over time
Related blog posts
- Is the Longevity Market growing now?
- What are the top startups in the longevity market?
